Eledon Pharmaceuticals, Inc. (ELDN) Dividend History

Eledon Pharmaceuticals, Inc. (ELDN) is a biotechnology company focused on developing novel therapies for inflammatory and neurodegenerative diseases. The company's lead programs target conditions such as amyotrophic lateral sclerosis (ALS) and organ transplant rejection, utilizing its proprietary Elededril platform to modulate the immune system and improve patient outcomes.

19800 Macarthur Blvd., Irvine, CA, 92612
Phone: 949-238-8090
Website: https://www.eledon.com

Dividend History

Eledon Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

    Eledon Pharmaceuticals' CEO will participate in a fireside chat at the Cantor Global Healthcare Conference, discussing the company's investigational product tegoprubart, an anti-CD40L antibody targeting immune-modulating therapies for conditions like kidney transplantation and ALS.

    GlobeNewswire Inc.
  • 4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com

    The article discusses four small-cap stocks that offer high risk and high reward potential as investors rotate their portfolios. The stocks are from the biotech and electric vehicle sectors, with analysts seeing significant upside but also inherent risks.

    Investing.com
    Featured Companies: ABOS BLNK
  • Are Medical Stocks Lagging DaVita (DVA) This Year?

    Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

    Zacks Investment Research
    Featured Companies: DVA
  • Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

    Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients. The company also reported updated data from its ongoing Phase 1b trial as of April 2024 from 13 participants, demonstrating that tegoprubart is generally safe and well-tolerated and supports tegoprubart’s potential to protect organ function in patients undergoing kidney transplantation. Aggregate mean estimated glomerular filtration rate (eGFR) – a measure of kidney function – measured above 60 mL/min/1.73m2 at all reported time points after day 30. Two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year. To date, three subjects discontinued the ...Full story available on Benzinga.com

    Benzinga
  • Penny Stocks To Buy Now? 4 To Watch This Week

    Penny stocks to watch this week. The post Penny Stocks To Buy Now? 4 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: GFAI GRAB MULN
Page data last updated 09/08/2025 17:50:12 UTC